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Purpose: To resolve the spectrum of causative retina-specific ATP-binding cassette transporter gene (ABCA4) gene
mutations in Portuguese Stargardt (STGD) patients and compare allele frequencies obtained in this cohort with those of
previous population surveys.
Methods: Using a microarray technique (ABCR400 gene chip), we screened all previously reported ABCA4 gene
mutations in the genomic DNA of 27 patients from 21 unrelated Stargardt families whose phenotypes had been clinically
evaluated using psychophysics and electrophysiological measurements. Furthermore, we performed denaturing high
performance liquid chromatography whenever one or both mutant alleles failed to be detected using the ABCR gene chip.
Results: A total of 36 mutant alleles (out of the 54 tested) were identified in STGD patients, resulting in a detection rate
of 67%. Two mutant alleles were present in 12 out of 21 STGD families (57%), whereas in four out of 21 (19%) of the
families, only one mutant allele was found. We report the presence of 22 putative pathogenic alterations, including two
sequence changes not found in other populations, c.2T>C (p.Met1Thr) and c.4036_4037delAC (p.Thr1346fs), and two
novel disease-associated variants, c.400C>T (p.Gln134X) and c.4720G>T (p.Glu1574X). The great majority of the
mutations were missense (72.7%). Seven frameshift variants (19.4%), three nonsense mutations (8.3%), and one splicing
sequence change (2.7%) were also found in STGD chromosomes. The most prevalent pathologic variant was the missense
mutation p.Leu11Pro. Present in 19% of the families, this mutation represents a quite high prevalence in comparison to
other European populations. In addition, 23 polymorphisms were also identified, including four novel intronic sequence
variants.
Conclusions: To our knowledge, this study represents the first report of ABCA4 mutations in Portuguese STGD patients
and provides further evidence of different mutation frequency across populations. Phenotypic characterization of novel
putative mutations was addressed.
Stargardt  disease  (STGD)  is  an  autosomal  recessive
macular dystrophy characterized by a childhood or juvenile
onset. STGD accounts for 7% of all retinal dystrophies and
affects about 1 in 10,000 individuals [1,2].
Kaplan  et  al.  [2,3]  mapped  the  Stargardt/fundus
flavimaculatus  disease  (STGD/FFM;  OMIM  248200)  to
chromosome  1p21-p22.  Molecular  analysis  of  the  ATP-
binding cassette transporter gene (ABCA4) gene, performed
by several groups, led to the identification of more than 490
sequence  variations  [4-7].  However,  such  high  allelic
heterogeneity within the 50 exons of ABCA4 gene makes it
difficult to predict the disease-causing variants. It is likely that
the wide variation in retinal phenotypes may be explained by
different combinations of ABCA4 mutations. Therefore, the
severity of phenotype is partly conditioned by the severity of
mutant allele(s) [8,9]. Furthermore, mutations in this gene
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have also been implicated in other retinal dystrophies, namely
autosomal  recessive  cone-rod  dystrophy  (arCRD;  OMIM
604116), retinitis pigmentosa (OMIM  601718), and to an
increased predisposition to age-related macular degeneration
(AMD; OMIM 153800) [4,10-12]. The detection of so many
sequence variants has enabled a heterogeneous frequency of
disease-associated alleles to be reported across populations
[6,9,12-18].
ABCA4 encodes a retina-specific ATP-binding cassette
(ABC) transporter protein that resides at the rim of cones and
rods outer segment discs and is involved in the all-trans-retinal
transport generated by activation of opsins [19]. An important
pathological feature of STGD/FFM and AMD is the abnormal
accumulation of lipofuscin in the retinal pigment epithelium
cells (lipofuscin accumulation occurs also in normal aging).
Progressive  atrophy  of  retinal  pigment  epithelium  and
degeneration of the underlying photoreceptors are thought to
be the cause of bilateral loss of central vision.
Here,  we  report  the  Portuguese  population-specific
ABCA4 mutant alleles found in a cohort of STGD patients.
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584Our goal was to further contribute to the establishment of
genotype-phenotype correlations involving ABCA4.
METHODS
Patients: Molecular screening of ABCA4 was performed in 27
STGD patients from 21 Portuguese families. Patients and their
family members were clinically evaluated at the University
Hospital of Coimbra (Coimbra, Portugal). Clinical diagnosis
of  STGD  was  based  on  full  ophthalmologic  examination,
including assessment of best-corrected visual acuity, slit-lamp
examination,  dilated  fundus  photography,  fluorescein
angiography,  color  vision  testing,  full-field
electroretinograms (ERG) and multifocal ERGs (mfERGs)
[20].  The  criteria  for  STGD  phenotype  included  bilateral
central vision loss and pigmentary macular lesions, normal
caliber of retinal vessels, absence of pigmented bone spicules,
and compatibility with recessive mode of inheritance. We
staged our patients according to the severity criteria of central
fundus changes described previously by Scholl and colleagues
[21]. After the objectives of the study were explained to each
participant, informed consent was obtained, and a peripheral
blood  sample  was  collected  and  preserved  frozen.  The
research was conducted in accordance with the tenets of the
Declaration of Helsinki and with the institutional guidelines
defined by the ethics committee of the Faculty of Medicine of
Coimbra.
Mutation analysis of ABCA4: Genomic DNA was extracted
using an automated DNA extractor (BioRobot EZ1, Qiagen,
Hilden, Germany). All the exons of ABCA4 (GDB370748,
GenBank  U88667.1)  were  PCR-amplified  as  described
previously [15] and used in the primer extension reaction
(APEX) on the ABCR400 microarray, which is, in essence, a
sequencing reaction on a solid support, as described elsewhere
in the literature [7]. In short, 5′-modified sequence specific
oligonucleotides are arrayed on a glass slide. In general, these
oligonucleotides are designed with their 3′ end immediately
adjacent to the variable site. PCR-prepared and fragmented
target nucleic acids are annealed to oligonucleotides on the
slide, followed by sequence-specific extension of the 3′ ends
of primers with dye-labeled nucleotide analogs (ddNTPs) by
DNA polymerase. Additionally, amplified fragments were
subjected  to  denaturing  high  performance  liquid
chromatography (dHPLC) screening whenever any or both
mutant alleles had failed to be identified in STGD patients,
using  a  WAVETM  DNA  Fragment  Analysis  System
(Transgenomic,  San  Jose,  CA),  in  which  the  temperature
conditions of dHPLC were designed and validated for all 50
exons,  as  described  by  other  [22].  All  abnormal
heteroduplexes obtained were then sequenced. Amplification
products were purified with QIA-quick Gel Extraction Kit
(Qiagen).  Sequencing  reactions  were  performed  using  the
four-dye  terminator  cycle  sequencing  ready  reaction  kit
(BigDye DNA Sequencing Kit; Applied Biosystems, Foster
City, CA). Sequencing products were purified through fine
columns  (Sephadex  G-501;  Princetown  Separations,
Adelphia, NJ) and resolved in an ABI Prism 3130 (Applied
Biosystems).
Analysis of haplotypes was performed in those families
whose patients had more than one mutation for the following
three microsatellite markers flanking the ABCA4 gene: TEL-
D1S435  (89.81  Mb),  D1S2804  (91.13  Mb),  and  ABCA4-
D1S236  (93.06  Mb)-CEN.  Samples  were  analyzed  in  an
automatic  genetic  analyzer  (ABIprism  3130,  Applied
Biosystems).
Control samples were selected from 55 unrelated healthy
individuals who did not have a personal or familiar history of
retinal disease. Anonymous blood donors were recruited at the
University Hospital of Coimbra.
RESULTS
In all, 27 patients from 21 Portuguese STGD families were
evaluated.  Our  study  detected  18  previously  reported
mutations  and  4  sequence  change  unreported  in  other
populations,  including  2  novel  disease-associated  variants
(Table 1). A total of 36 mutant alleles (out of the 54 tested)
were  identified  in  STGD  patients.  Gene  chip  screening
allowed us to achieve a mutation detection rate of 55%. When
we  consider  the  combination  of  microarray  and  dHPLC
technologies, we were able to identify two mutant alleles in
12 out of 21 STGD families (57%), whereas we found only
one mutant allele in four out of 21 (19%) of the families. No
mutation was detected in the remaining five families (24%).
Therefore, with the combined strategy a detection rate of 67%
was obtained. Most disease alleles carried missense mutations
(27/36  corresponding  to  72.7%).  However,  frameshift
variants (7/36; 19.4%), nonsense mutations (3/36; 8.3%), and
one splicing sequence change (2.7%) were also identified in
STGD  chromosomes.  When  patients  had  more  than  one
mutation,  allelic  segregation  analyses  of  the  families
(including parents and siblings) was performed to establish
the haplotype and disease-associated haplotypes cosegregated
within all families analyzed. Interestingly, four disease alleles
were found to be double mutants (families 5, 11, and 19), two
of them carried by one STGD patient. These findings led to
the identification of the following three variants acting in cis
(complex alleles): p.[Ser1642Arg]+[Val1681_Cys1685del],
found in 9.5% of the families; p.[Val931Met]+[Ser1642Arg],
found  in  4.8%  of  the  families,  and  p.[Met1Val]+
[Arg2030Gln], found in 4.8% of the families (for details, see
Table 1). Most of the mutations detected have been reported
as  STGD-associated  variants:  p.Met1Val,  p.Asn96Asp,
p.Arg290Trp, p.Val931Met, p.Gly1961Glu, p.Leu2027Phe,
p.Arg2030Gln, p.Asp1048fs, and IVS40+5G>A.
Although most of the mutations were found in one family,
five  disease-associated  alleles  were  detected  in  unrelated
STGD  families  (p.Leu11Pro,  p.Asp1048fs;  p.Gly1961Glu;
p.Ser1642Arg; p.Val1681_Cys1685del; p.Val931Met). The
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586most prevalent disease-associated variant was the missense
mutation  p.Leu11Pro,  accounting  for  11%  (4/36)  of  the
disease chromosomes. This variant was present in four out of
21 families (19%). The p.Gly1961Glu mutation, associated
with AMD, was found in 9.5% of our patients. This is a
common variant observed in patients of European origin,.
Among  the  four  null  mutations  unreported  in  other
populations,  the  c.2T>C  transition  at  the  initiation  codon
(p.Met1Thr)  was  found  in  homozygous  state  in  only  one
STGD patient (Family 9; Figure 1A). This double null mutant
STGD  patient  had  an  early  onset  and  showed  moderate
macular changes and a dramatic visual loss two years after
disease  onset.  Familial  segregation  was  confirmed,  and
consanguinity  was  denied  by  the  family.  However,  both
branches of the family come from neighboring villages. This
missense  mutation  p.Met1Thr  was  absent  in  the  102
chromosomes from healthy unrelated Portuguese controls and
was recently reported by us in a STGD relative [20].
The  STGD  patient  from  Family  12  is  a  compound
heterozygous  with  p.Val931Met  and  a  novel  nonsense
mutation at exon 33 (p.Glu1574X; Figure 1B). Disease onset
for  this  patient  was  at  age  43.  Ophthalmic  examination
revealed moderate central retinal changes, decreased mfERG
responses exclusively in the central 15 degrees, and decreased
visual acuity.
Finally, two null mutations were identified in a Brazilian
family of Portuguese ancestry (Family 14; Figure 1C). Both
severely affected patients (monozygous twins) were found to
be compound heterozygous with a novel nonsense mutation
at exon 4 (p.Gln134X) and a frameshift in exon 27 caused by
a deletion (c.4036_4037delAC leading to p.Thr1346fs); see
Figure 1C. This last mutation was recently found by us in a
STGD  relative  [20],  but  has  not  been  reported  in  other
populations.
Several  polymorphisms  were  also  identified  and  are
summarized in Table 2. In all, 23 polymorphic changes were
detected,  four  of  which  are  novel  intronic  putative
nonpathogenic  variants  (IVS7+8T>C;  IVS14+47T>C;
IVS19+34C>T;  IVS22–19G>A).  Allelic  segregation
analyses were performed in all families whose patients had
more  than  one  mutation  (except  Family  19).  Disease-
associated haplotypes were found to be segregated within the
families.
DISCUSSION
To our knowledge, this is the first report of ABCA4 mutations
in Portuguese STGD patients. To date, over 490 variants have
been reported in the largest gene of the ABC family: ABCA4
gene. Some of the variants that have been described are rare
and may even be specific to certain specific geographic areas.
Figure  1.  Pedigrees,  elution  dHPLC
profiles, and sequence changes for each
new  disease-associated  ABCA4
mutations are shown: A - p.Met1Thr (c.
2T>C); B - p.Glu1574X (c.4720G>T);
C  -  p.Gln134X  (c.400C>T);  and
p.Thr1346fs (c.4036_4037delAC). In B
and C, the forward sequence changes
are  shown.  In  A,  the  reverse  normal,
heterozygous, and homozygous mutant
sequences  are  presented.  The  arrows
indicate the individuals genotyped from
each  family,  including  the  STGD
proband (filled symbols) and siblings.
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588Therefore different frequency distribution across populations
have been reported. In this cohort of Portuguese patients, the
most  prevalent  variant  found  in  19%  of  the  families,
Leu11Pro, is considered a rare mutation in other populations.
Even  in  Spain,  and  in  spite  of  its  geographic  proximity,
Leu11Pro frequency is significantly lower (<1%) in macular
degenerations associated with ABCA4 mutations [17,23]. This
likely moderate missense substitution, involving a conserved
nonpolar amino acid residue, is located in the intracytoplasmic
domain of the ABCA4 protein; it has been reported in FFM
and in arCRD [12,23]. The most frequent mutation in various
European  countries  is  p.Gly1961Glu.  Although  its
frequencies range between 11%–21%, it seems to be less
common in the Portuguese population (9.5%). Its prevalence
is  similar  to  the  one  found  in  other  south  European
populations, namely 6.6% in Spanish STGD patients [7,23].
Interestingly, the p.Arg1129Leu, which is the most frequent
variant in Spain (14.5%) [20], was not found in any of the 21
STGD  Portuguese  families  studied.  These  findings  are
consistent with studies on genetic diversity. Those studies
concluded that the Iberian population is not a genetic edge of
European variation and might have a higher level of diversity
than  some  neighboring  populations,  receiving  significant
North and sub-Saharian African influences at different times
[24]. Therefore, this study might provide further evidence of
the  importance  of  molecular  analysis  of  this  considerable
large and polymorphic gene in different populations.
Also  identified  in  our  patient  population  were  four
putative  pathogenic  mutations,  two  of  which  are  novel
variants, that have not been reported in other populations:
Family  9,  c.2T>C  (p.Met1Thr);  Family  14,  c.400C>T
(p.Gln134X)  and  c.4036_4037delAC  (p.Thr1346fs);  and
Family  12,  c.4720G>T  (p.Glu1574X).  The  p.Met1Thr
substitution was detected in both chromosomes of a severely
affected STGD patient, whose heterozygous mother presented
subclinical impairment of retinal function even in absence of
any fundus change, as described in our previous report [20].
Interestingly, this variant is the second substitution residing
in the Met1 residue. Previously, Briggs and colleagues [6]
described the p.Met1Val in a heterozygous STGD patient with
no  other  sequence  change  identified.  Therefore,  this  null
mutation may lead to early disease onset, moderate central
fundus changes (even as early as one year after disease onset),
and residual visual acuity when in the homozygous state.
Future functional studies should assess the relative severity of
this variant to clarify whether this mutation can be pathologic
even in heterozygous state as has been suggested for other
ABCA4 mutations, namely p.Gly1961Glu [25-27]. The novel
nonsense  mutation,  a  G>T  transversion  leading  to
p.Glu1574X, involves a highly conserved nucleotide in the
ortholog bovine and mouse proteins. This sequence change
causes  a  protein  truncation  before  NBD-2,  a  functional
domain  that  is  believed  to  diminish  ATP  hydrolysis  by
NBD-1,  without  altering  the  basal  ATPase  activity  [28].
Segregation analysis was limited to available relatives: the
mother, from whom the p.Val931Met al.lele was inherited,
and the paternal aunt, who did not carry any of these disease
alleles. The p.Val931Met mutation resides in the NBD-1,
what according to the model proposed by Sun et al., has a
severe impact in ABCA4 protein function, eliminating both
basal  and  retinal-stimulated  ATPase  activity  [28].
Interestingly, clinical examination of this patient revealed that
retinal damage was limited to the central 15 degrees, a relative
late  onset  and  moderate  central  fundus  changes  after  the
second year of disease onset. Therefore, the combination of
the two alleles results in a relatively late disease onset with a
moderate retinal dysfunction progression.
In Family 14, compound heterozygous of a nonsense
mutation at exon 4 (p.Gln134X) and a frameshift in exon 27
(p.Thr1346fs), were associated to a very early disease onset.
Even after only 4 years of disease onset, both patients were
severely  affected  and  shared  dramatically  reduced  visual
acuities. Their mfERG results revealed severely decreased
response amplitudes (almost abolished) within the central 30
degrees of the retina and impaired color vision in all three
main  chromatic  axes.  This  stop  mutation  affects  a  100%
conserved  nucleotide,  before  any  of  the  ATP  binding
domains, leading to a premature stop codon of 134 amino acid
residue out of the 2,273 residues of ABCA4 protein that likely
undergo  nonsense-mediated  decay.  Additionally,  in  this
family, we found a second null mutation that resides between
the  two  homologous  halves  of  ABCA4,  a  deletion  of  a
dinucleotide AC at codon 1346. An insertion of a dinucleotide
CA affecting the same codon has been detected and has been
found to be associated with a severe phenotype (arCRD) [6].
Therefore,  both  novel  variants  are  compatible  with  the
dramatically  severe  phenotype  observed  in  these  STGD
patients.
Interestingly, in patients from families 9 and 14, two null
mutant alleles were identified in each patient. It is worth
noting that even considering the severe phenotype presented
by those patients, they were diagnosed with STGD disease.
However, according to the proposed model, the combination
of two null alleles likely accounts to a more severe phenotype
as retinitis pigmentosa or arCRD [29]. Since in both families,
STGD patients had short disease progression, we speculate
whether their phenotype may evolve (in later stages) to a more
severe retinal impairment such as arCRD.
In  this  study,  genotype-phenotype  correlations  were
addressed  based  on  previous  extensive  phenotype
characterization. However, the value of the ABCA4 model
proposed for genotype-phenotype might be limited in larger
families because of the intrafamiliar phenotypic variation and
since the model is mainly based on large set of single patients,
not on extensive families. Mutation analysis was performed
with a combination of complementary techniques: ABCA4
gene chip, dHPLC, and direct sequencing. This was found to
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589be  a  successful  strategy  resulting  in  high  mutation  rate
detection (67%), compared to other surveys [6,18,30,31]. It is
worth to note the efficiency, specificity and high detection rate
of the ABCR400 chip. However, in 3 out of the 21 studied
families (14.3%; families 9, 12, and 14), the causal mutations
were  detected  using  a  combination  of  dHPLC  and  direct
sequencing technology.
Functional studies to evaluate the biochemical defects
caused  by  the  numerous  variants  identified  will  help
understanding the relative impact of the complex (and single)
heterozygous. Therefore, those studies will improve genetic
counselling of families affected with ABCA4-related retinal
diseases.
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